Ifosfamide-induced encephalopathy and movement disorder

Area of Science:

• Neuro-oncology
• Pediatric Neurology
• Clinical Toxicology

Background:

• Ifosfamide is a crucial chemotherapeutic agent for various solid tumors.
• Central nervous system (CNS) toxicity is a known adverse effect of ifosfamide.
• The precise mechanisms underlying ifosfamide-induced neurotoxicity are not fully understood.

Purpose of the Study:

• To report two pediatric cases of hemiballismic movements associated with ifosfamide-induced encephalopathy.
• To highlight a rare neurological complication of ifosfamide treatment in children.
• To explore potential therapeutic interventions for this condition.

Main Methods:

• Case report of two pediatric patients undergoing ifosfamide chemotherapy.
• Clinical observation and documentation of neurological symptoms, specifically hemiballismus.
• Review of medical literature for similar cases and treatment outcomes.

Main Results:

• Two pediatric patients developed hemiballismic limb movements during ifosfamide treatment.
• These movements occurred in the context of ifosfamide-associated encephalopathy.
• One patient showed potential improvement in encephalopathy and movements after methylene blue and thiamine administration.

Conclusions:

• Ifosfamide-induced hemiballismus is a rare but significant neurological complication in pediatric patients.
• The findings suggest a potential role for methylene blue and thiamine in managing ifosfamide neurotoxicity.
• Further research is warranted to elucidate the mechanisms and optimize treatment strategies.